{"id":98,"date":"2024-02-15T08:12:00","date_gmt":"2024-02-15T12:12:00","guid":{"rendered":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/?p=98"},"modified":"2024-02-16T16:27:15","modified_gmt":"2024-02-16T20:27:15","slug":"guidance-for-controlling-drug-prices","status":"publish","type":"post","link":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/2024\/02\/15\/guidance-for-controlling-drug-prices\/","title":{"rendered":"Guidance for Controlling Drug Prices"},"content":{"rendered":"<p>The Federal Trade Commission (FTC) has announced its support of the federal government\u2019s use of \u201cmarch-in rights\u201d as a mechanism to control the price of pharmaceuticals. The National Institute of Standards and Technology (NIST) late last year\u00a0<a href=\"https:\/\/www.federalregister.gov\/documents\/2023\/12\/08\/2023-26930\/request-for-information-regarding-the-draft-interagency-guidance-framework-for-considering-the\" target=\"_blank\" rel=\"noopener\">issued<\/a>\u00a0its \u201cDraft Interagency Guidance Framework for Considering the Exercise of March-In Rights\u201d that would fundamentally change the use of march-in rights by allowing the government to exercise price control under the Bayh-Dole Act, which the FTC announced its support for last week. This shift is the latest effort by federal agencies to lower drug prices in the wake of President Joe Biden\u2019s\u00a0<a href=\"https:\/\/www.whitehouse.gov\/briefing-room\/presidential-actions\/2021\/07\/09\/executive-order-on-promoting-competition-in-the-american-economy\/\" target=\"_blank\" rel=\"noopener\">Executive Order<\/a>\u00a0on Promoting Competition in the American Economy.<\/p>\n<p><a href=\"https:\/\/www.duanemorris.com\/alerts\/ftc_supports_marching_in_patent_rights_mechanism_control_drug_prices_0224.html\" target=\"_blank\" rel=\"noopener\">Read the full\u00a0<em>Alert\u00a0<\/em>on the Duane Morris website.<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>The Federal Trade Commission (FTC) has announced its support of the federal government\u2019s use of \u201cmarch-in rights\u201d as a mechanism to control the price of pharmaceuticals. The National Institute of Standards and Technology (NIST) late last year\u00a0issued\u00a0its \u201cDraft Interagency Guidance Framework for Considering the Exercise of March-In Rights\u201d that would fundamentally change the use of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/blogs.duanemorris.com\/antitrustlaw\/2024\/02\/15\/guidance-for-controlling-drug-prices\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Guidance for Controlling Drug Prices&#8221;<\/span><\/a><\/p>\n","protected":false},"author":6,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[11,28,29,24,16,26,27,25,13,17],"ppma_author":[5],"class_list":["post-98","post","type-post","status-publish","format-standard","hentry","category-general","tag-antitrust","tag-bayh-dole-act","tag-drug-prices","tag-frederick-ball","tag-ftc","tag-nist","tag-pharmaceuticals","tag-president-biden","tag-sarah-olaughlin-kulik","tag-sean-mcconnell"],"authors":[{"term_id":5,"user_id":6,"is_guest":0,"slug":"duanemorris3","display_name":"Duane Morris","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/843ff6e7a8fe5fc92109b47a45f34b6cf0ea499e6e788db23456c838b0ae6747?s=96&d=blank&r=g","0":null,"1":"","2":"","3":"","4":"","5":"","6":"","7":"","8":""}],"_links":{"self":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts\/98","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/comments?post=98"}],"version-history":[{"count":0,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/posts\/98\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/media?parent=98"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/categories?post=98"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/tags?post=98"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/blogs.duanemorris.com\/antitrustlaw\/wp-json\/wp\/v2\/ppma_author?post=98"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}